Biomatik Corp

Elarex Inc, based in Burlington, ON, specializes in stabilizing biologicals, particularly vaccines, through a proprietary technology that combines viral vectors with optimized formulations and drying processes. Their innovative platform, PT120D, offers exceptional temperature stability, allowing vaccines typically requiring -80°C storage to be stored at -40°C, significantly enhancing their transportability and shelf life. Founded in 2019 by Robert DeWitte and Carlos Filip, Elarex has evolved from research conducted at McMaster University, resulting in numerous publications and patents. The company's technology not only stabilizes vaccines but also benefits a wide array of biotherapeutics, including small molecules, enzymes, DNA, and RNA, positioning Elarex as a leader in the fight against infectious diseases. Generated from the website

Vital Biosciences Inc., based in Mississauga, Ontario, is at the forefront of transforming lab testing and diagnostics to facilitate radically accessible healthcare. Their innovative product, the VitalOne, aims to deliver comprehensive lab-grade results virtually instantaneously using only a small blood sample, enabling healthcare providers to close care gaps and engage patients effectively. The company harnesses cutting-edge technologies, including robotics, biochemistry, computer vision, and microfluidics, to set a new standard in diagnostic healthcare. Currently, the VitalOne technology is in development and has not yet been evaluated or cleared by regulatory authorities, but Vital Biosciences is making significant strides towards making this permanent fixture in health monitoring available. Generated from the website

Owen-Barry Pharmaceuticals, Inc, situated in Toronto, Ontario, is a company focused on innovative drug development. Led by a team of experienced individuals, including founders Michael Poulter Ph.D. and John Poulter B.A., C.F.A., the company is committed to advancing scientific research in the pharmaceutical field. With expertise from individuals like Lawrence Mahan Ph.D. and Michael Rogawski, MD, PhD, the management team ensures a strategic approach to drug discovery and development. The board of directors, comprising professionals such as Caroline Schild-Poulter, Ph.D., and Rod Prat, B.A., M.B.A., provides guidance and oversight to steer the company towards success. Additionally, Owen-Barry Pharmaceuticals, Inc benefits from the valuable insights of scientific and clinical advisors like Pavel Klein, MD, and Peter Carlen, MD, FRCPC. With a focus on technological advancements and support from investors, the company strives to make significant contributions to the pharmaceutical industry. Generated from the website content